By Gina Shaw
Las Vegas—The frenzied pace of oncology drug approvals slowed down last year; the FDA approved only nine new cancer drugs (or indications for previously approved drugs) in 2016, compared with 18 in 2015. But oral oncolytics continue to make up a significant percentage of new cancer drug approvals—four of the nine in 2016, nine of the 18 in 2015 and four of the nine in 2014, according to CenterWatch. And of the more than 830 cancer drugs currently in the pipeline, at
FEBRUARY 14, 2017